Immunomodulation by controlling ELR+ proinflammatory chemokines levels with the long non-coding RNA UMLILO

A novel approach for detecting new anti-HIV targets that modulate HIV infection.

Applications: Human microRNA mimics and inhibitors that enhance and suppress HIV replication

Intellectual Property: EPO-Granted and other patents application still pending.

Technology Field: Pharmaceuticals, Biotechnology

Business Opportunity: Investment for further technology development and conduct relevant trials.

Technology Description: The present invention pertains generally to immunomodulation by altering levels of the proinflammatory chemokines. In particular, the invention relates to methods of modulating an immune response with UMLiLo, a long non-coding RNA that regulates expression of the ELR+ proinflammatory chemokines. The invention further relates to methods of treating inflammatory, autoimmune, and infectious diseases, immunodeficiency, and cancer by reducing levels of chemokines.

Benefits & Advantages: Novel mechanisms for immunomodulation by altering levels of the proinflammatory chemokines and for using same approach treating diseases that have an inflammatory related physiology

Inventors: Dr Stephanie Fanucchi Dr Musa Mhlanga Youtaro Shibayama

Media
Funzani.jpg